Bivalirudin in venovenous extracorporeal membrane oxygenation.
Optimal anticoagulation plays a pivotal role in successful outcome of extracorporeal membrane oxygenation (ECMO). Heparin has been the anticoagulant of choice owing to its advantages like easy monitoring and reversibility. However, if heparin resistance is encountered, one has to decide whether to treat heparin resistance with fresh-frozen plasma or antithrombin concentrates or to choose one of the heparin alternatives for anticoagulation. We report a case of heparin resistance resulting from antithrombin III deficiency in a patient on venovenous ECMO, in which anticoagulation was managed with bivalirudin. The dose of bivalirudin for anticoagulation in ECMO has not been standardized and different authors have reported different doses. We found a bivalirudin dose of .1-.2 mg/kg/h to be adequate to maintain a target activated clotting time of 200-220 seconds. Platelet counts were stable throughout and no major bleeding or thrombotic complications took place. We found bivalirudin to be a feasible and effective anticoagulant and safe to use for long durations in ECMO without any major complications.
Aman
A
Jyoti
Arun
A
Maheshwari
Elvin
E
Daniel
Amit
A
Motihar
Rajpal Singh
RS
Bhathiwal
Deevakar
D
Sharma
D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects*; D006440:Hemofiltration / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006629:Hirudins; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000517:prevention & control*; D013927:Thrombosis / Q000517:prevention & control*; D016896:Treatment Outcome
D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin